Download PDF
Thromb Haemost 1977; 38(03): 0701-0706
DOI: 10.1055/s-0038-1651886
Original Article
Schattauer GmbH

Heparin Elimination in Patients with Liver Cirrhosis

Arne N. Teien
1   Medical Department A, Aker Hospital, Oslo 5, Norway
› Author Affiliations
Further Information

Publication History

Received 25 October 1976

Accepted 24 May 1977

Publication Date:
04 July 2018 (online)

    Permissions and Reprints

Summary

Heparin (100 U/kg body-weight) was injected intravenously, and heparin concentration in plasma determined by polybrene titration. Mean heparin half-life was 117.8 min in a group of patients with liver cirrhosis and normal renal function (n = 6) as compared to 74.0 min in the normal group (n = 6). The difference between the two groups is statistically significant (p ≈ 0. 02). Heparin half-life was correlated to galactose half-life in the patients (r = 0.83, p = 0. 05). The findings suggest that heparin is metabolized in the liver. There was a significant fall in antithrombin III activities in the normals, but not in the patients. A possible explanation may be that the normal liver removes heparin bound to antithrombin III, and that this function is impaired in liver cirrhosis.

 

  • References

  • 1 Godal H. C. 1960; A comparison of two heparin-neutralizing agents: Protamine and polybrene. Scandinavian Journal of Clinical and Laboratory Investigation 12: 446.
    CrossrefPubMedGoogle Scholar
  • 2 Hodges J. L, Lehmann E. L. 1964. Basic Concepts of Probability and Statistics. Holden-Day, Inc.; San Francisco.:
    Google Scholar
  • 3 Höök M. 1976 Personal communication.
    PubMedGoogle Scholar
  • 4 Jacques B, Keeri-Szanto E. 1952; Heparinase. Distribution of enzyme in various tissues and its action on natural heparin and certain synthetic anticoagulants. Canadian Journal of Biochemistry 30: 353.
    PubMedGoogle Scholar
  • 5 Monkhouse F. C. 1954; Physiological factors concerned with the removal of injected heparin from the circulating blood. American Journal of Physiology 178: 223.
    PubMedGoogle Scholar
  • 6 Ødegård O. R, Lie M, Abildgaard U. 1975; Heparin cofactor activity measured with an amidolytic method. Thrombosis Research 6: 287.
    CrossrefPubMedGoogle Scholar
  • 7 Ødegård O. R, Abildgaard U, Lie M. 1976; Antifactor Xa activity measured with amidolytic methods. Haemostasis 5: 265.
    PubMedGoogle Scholar
  • 8 Olsson P, Lagergren H, Ek S. 1963; The elimination from plasma of intravenous heparin. An experimental study on dogs and humans. Acta Medica Scandinavica 173: 619.
    PubMedGoogle Scholar
  • 9 Perry P. J, Herron G. R, King J. C. 1974; Heparin half-life in normal and impaired renal function. Clinical Pharmacology and Therapeutics 16: 514.
    PubMedGoogle Scholar
  • 10 Piper J. 1947; The fate of heparin in rabbits after intravenous injection. Acta Pharmacologica 3: 373.
    PubMedGoogle Scholar
  • 11 Schuytema E. C, Cushing I. B. 1958; Attempts to extract mammalian heparinase. Federation Proceedings; Federation of American Societies for Experimental Biology 17: 307.
    PubMedGoogle Scholar
  • 12 Shanberge J. N, Kambayashi J. 1975. Studies on platelet-heparin interactions utilizing a tritium-labelled heparin. In: Abstracts Vth Congress of the International Society on Thrombosis and Haemostasis. Paris: 458.
    Google Scholar
  • 13 Teien A. N, Bjørnson J. 1976; Heparin elimination in uraemic patients on haemo-dialysis. Scandinavian Journal of Haematology 17: 29.
    PubMedGoogle Scholar
  • 14 Teien A. N, Lie M. 1975; Heparin assay in plasma: A comparison of five clotting methods. Thrombosis Research 7: 777.
    CrossrefPubMedGoogle Scholar
  • 15 Tengström B, Hjelm M, Verdier C.-H. de, Werner I. 1967; Intravenous galactose tolerance test with the use of an enzymatic method for the determination of galactose. American Journal of Digestive Diseases 12: 853.
    CrossrefPubMedGoogle Scholar